Yes folks, if you do not already know, Endo has a new product in the pipeline currently in trials called Axomadol. And if you have not guessed it already, it is basically Tramadol with a single hydroxy group added. I am not kidding, they actually took Tramadol and added an -OH somewhere to it and have patented it, and are now trying to get it approved.
I am just curious how it will compare to Nucynta and if it will go that route or nonscheduled. It is apparently indicated for moderate to severe pain. Very interesting!
I have never been much of a fan of taking "new" drugs. I have had some really rotten, bleeding stomach, side effects from drugs that were later taken off the market.
Having said that, Axomadol sounds like something I would be willing to try.
I was really hopeful about the Nucynta but when it went Schedule II I knew there was no sense in my asking my doc.
Tramadol, Motrin 800, Darvocet, I can get by the truckload. Problem is, they do next to nothing to help the pain.
Personally, I think the pharmaceutical companies are racing to come up with drugs that can go Sched III or lower because of the negatives associated with drugs like Oxycodone and Hydrocodone. I only wish they were racing more like the turtle and not the hare! LOL
HAHA, great post Pamipa! I agree, and I think it is also great that pharmaceutical companies are still tackling pain issues. It is the most prevalent complaint in American Healthcare. As I think was mentioned in another thread, something like 1 in 4 Americans claim to be in chronic pain of some sort. It is breath of fresh air to know that they are looking for more options for pain patients rather then just what is on the market. I honestly cannot wait to see how they schedule this drug though.
You have obviously done your homework on this drug. Given its almost exact composition to Tramadol, it will probably be unscheduled federally. That is assuming Tramadol does not get scheduled in the meantime. I think you're right about how absolutely worthless it is to add this analgesic to the market given its similarity to Tramadol.
Previous Topic
Index